Long COVID
Conditions
Interventions
Lactoferrin 1200 mg/day versus Placebo
Sponsors
Stichting O&O Franciscus Gasthuis & Vlietland
Eligibility
Inclusion criteria
Inclusion criteria: - Persistent or newly developed long COVID symptoms at least 12 weeks post-primary SARS-CoV-2 infection - Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9 months - Adult patients with age >18 years
Exclusion criteria
Exclusion criteria: - Patients admitted to the ICU (COVID-19-related) - COVID-19-related cardiac or pulmonary tissue damage - Acute infection or current systemic immunological disorders - Oral and/or inhaled use of corticosteroids or use of other immune-modulatory medication - Current psychiatric disorders - Communication difficulties - Pregnant or lactating women - Age >70 years - Patients with milk allergy or a known or suspected allergy or any contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can be used by individuals with lactose intolerance)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| - Do anxiety and depressive symptoms diminish (faster) with the use of lactoferrin? - Does the use of lactoferrin (faster) improve cognitive function? - Does muscle strength recover (faster) with the use of lactoferrin? - Does the use of lactoferrin have an effect on inflammatory blood parameters? - How do changes in subjective health parameters correlate with circulating biomarkers? | — |
Primary
| Measure | Time frame |
|---|---|
| -Do fatigue symptoms diminish faster with the use of lactoferrin combined with usual care compared to usual care solely? | — |
Contacts
Public ContactGert-Jan Braunstahl
Franciscus Gasthuis & Vlietland
Outcome results
None listed